首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Population pharmacokinetic modeling of the Qishe pill in three major traditional Chinese medicine-defined constitutional types of healthy Chinese subjects: study protocol for a randomized controlled trial
【2h】

Population pharmacokinetic modeling of the Qishe pill in three major traditional Chinese medicine-defined constitutional types of healthy Chinese subjects: study protocol for a randomized controlled trial

机译:三种主要中药定义的健康中国人体质类型的气射丸的群体药代动力学模型:一项随机对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundHigh incidences of neck pain morbidity are challenging in various situations for populations based on their demographic, physiological and pathological characteristics. Chinese proprietary herbal medicines, as Complementary and Alternative Medicine (CAM) products, are usually developed from well-established and long-standing recipes formulated as tablets or capsules. However, good quantification and strict standardization are still needed for implementation of individualized therapies. The Qishe pill was developed and has been used clinically since 2009. The Qishe pill’s personalized medicine should be documented and administered to various patients according to the ancient TCM system, a classification of personalized constitution types, established to determine predisposition and prognosis to diseases as well as therapy and life-style administration. Therefore, we describe the population pharmacokinetic profile of the Qishe pill and compare its metabolic rate in the three major constitution types (Qi-Deficiency, Yin-Deficiency and Blood-Stasis) to address major challenges to individualized standardized TCM.
机译:背景技术基于人群的人口统计学,生理学和病理学特征,在各种情况下,颈部疼痛发病率高发对人群构成挑战。中成药,作为补充和替代医学(CAM)产品,通常是由成熟的配方制成片剂或胶囊,并由来已久。但是,仍然需要良好的量化和严格的标准化来实施个性化疗法。气射丸的研制自2009年开始投入临床使用。应根据古代中医系统,对气射丸的个性化药物进行记录和管理,并将其用于个性化体质类型的分类,并确定疾病的易感性和预后作为治疗和生活方式管理。因此,我们描述了七社丸的总体药代动力学特征,并在三种主要体质类型(气虚,阴虚和血瘀)中比较了其代谢率,以应对个体化标准化中药的重大挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号